← feed

Is NCT03340753 results overdue?

Yes — results are overdue. Primary completion was 2017-11-22; the FDAAA-801 reporting deadline (2018-11-22) passed 2768 days ago and no results are posted on ClinicalTrials.gov.

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT IDNCT03340753 ↗
SponsorKBP Biosciences (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-11-22 (ACTUAL)
Reporting deadline2018-11-22 (completion + 365d)
Days overdue2768
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 d1cf7de414358319… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03340753. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →